• SPX
  • $5,762.48
  • 0.42 %
  • $24.31
  • DJI
  • $42,330.15
  • 0.04 %
  • $17.15
  • N225
  • $38,651.97
  • 1.93 %
  • $732.42
  • FTSE
  • $8,250.24
  • 0.16 %
  • $13.29
  • IXIC
  • $18,189.17
  • 0.38 %
  • $69.58
Teligent, Inc. (TLGT) Stock Price, News & Analysis

Teligent, Inc. (TLGT) Stock Price, News & Analysis

Currency in USD Disclaimer

NA

NA

NA

Day's range
$0.17
Day's range
$0.21
50-day range
$0.165
Day's range
$0.494
  • Country: US
  • ISIN: US87960W2035
52 wk range
$0.02
Day's range
$1.6
Notice: This company has been marked as potentially delisted and may not be actively trading.


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score N/A
  • Piotroski Score N/A
  • Grade Hold
  • Symbol (TLGT)
  • Company Teligent, Inc.
  • Price $0.17
  • Changes Percentage (-13.85%)
  • Change -$0.03
  • Day Low $0.17
  • Day High $0.21
  • Year High $1.60

Teligent, Inc., formerly Igi Laboratories Inc, is a specialty generic pharmaceutical company. Under the Company's own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 35 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2018. It provides development, formulation and manufacturing services to the pharmaceutical, over-the-counter (OTC) and cosmetic industries. It focuses on developing, manufacturing and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex and ophthalmic dosage forms, and managing its contract manufacturing and formulation services business. Its pipeline included 20 Abbreviated New Drug Application (ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2018.

  • Last Earnings N/A
  • Ex-Dividend for 5/16 Dividend 12/13/1995
  • Dividend Payable N/A
  • Today N/A
  • Next Earnings (Estimated) 08/16/2021
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$4.31
  • Trailing P/E Ratio -0.040264562543514
  • Forward P/E Ratio -0.040264562543514
  • P/E Growth -0.040264562543514
  • Net Income $0

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.